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Abstract
Background: Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders caused by defects
in the steroid 21 hydroxylase gene (CYP21A2). We studied the spectrum of mutations in CYP21A2 gene in
a multi-ethnic population in Pakistan to explore the genetics of CAH.
Methods: A cross sectional study was conducted for the identification of mutations CYP21A2 and their phenotypic
associations in CAH using ARMS-PCR assay.
Results: Overall, 29 patients were analyzed for nine different mutations. The group consisted of two major forms
of CAH including 17 salt wasters and 12 simple virilizers. There were 14 phenotypic males and 15 females
representing all the major ethnic groups of Pakistan. Parental consanguinity was reported in 65% cases and was
equally distributed in the major ethnic groups. Among 58 chromosomes analyzed, mutations were identified in 45
(78.6%) chromosomes. The most frequent mutation was I2 splice (27%) followed by Ile173Asn (26%), Arg 357 Trp
(19%), Gln319stop, 16% and Leu308InsT (12%), whereas Val282Leu was not observed in this study. Homozygosity
was seen in 44% and heterozygosity in 34% cases. I2 splice mutation was found to be associated with SW in the
homozygous. The Ile173Asn mutation was identified in both SW and SV forms. Moreover, Arg357Trp manifested
SW in compound heterozygous state.
Conclusion: Our study showed that CAH exists in our population with ethnic difference in the prevalence of
mutations examined.
Background
Congenital adrenal hyperplasia (CAH; OMIM # 201910)
is an autosomal recessive disorder, characterized
by defects in any of the five-enzymes required to synthe-
size cortisol. In 95% of the cases, deficiency of 21-
hydroxylase enzyme (21OH) was observed, which results
in reduced synthesis of cortisol and aldosterone. Over-
production of adrenal androgens causes prenatal and
postnatal virilization. CAH phenotypes vary with the
degree of enzyme deficiency. Prenatal virilization in
newborns females and salt wasting (SW-CAH) in both
sexes, during the neonatal period can occur due to com-
plete enzyme deficiency. On the other hand, partial
enzyme deficiency leads to classic simple virilization
form (SV-CAH) presenting with prenatal virilization in
females and pseudo-precocious puberty in both males
and females. Mild deficiency of 21OH causes non-
classical disease (NC-CAH) with pseudo-precocious pub-
erty, hirsutism, acne and reduced fertility at a later age [1].
Clinical diversity in CAH is primarily due to mutations
in CYP21A2 gene, which encodes 21OH. CYP21A2 is
located within the human leukocyte antigen class III
region on the short arm of chromosome 6, adjacent to a
highly homologous pseudo gene (CYP21A1P). Both are
3-4 kb long and each gene consists of 10 exons. Pseudo-
gene has some deleterious mutations, which makes it
non-functional. The majority of mutations in the steroid
21-hydroxylase gene have originated from this highly
homologous adjacent pseudo-gene [1,2].
Analyses of different populations show that 95% of the
CAH cases are caused by 9 specific point mutations and
deletions in the CYP21A2 gene. Specific mutations
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producing a clinical form of 21OH enzyme deficiency. In
majority of patients, strong correlation between genotype
and clinical disease presentation has been shown [3].
The data on CAH in Pakistan is very limited. In a pre-
vious study, we have reported CAH cases registered in our
Hospital. Some of the features noted were delay in diagno-
sis, inappropriate gender assignment at birth, increase in
the number of deaths in the family and high degree of con-
sanguinity [4-6]. Moreover, as a result of late diagnosis, a
large number of CAH patients in Pakistan develop genital
malformations [6]. Therefore, this study was carried out to
identify the spectrum of mutations in CYP21A2 gene, and
to correlate genotype with the phenotype in a randomly
selected cohort of CAH patients, which has been pre-
viously reported in our studies on CAH. The knowledge of
the mutations in CYP21A2 gene will assist and promote
prenatal diagnosis of CAH in the local population.
Methods
Study Subjects
This study was conducted at the Department of Pathology
and Microbiology, The Aga Khan University and was
approved by the Hospital Ethics Committee. Patients diag-
nosed with CAH were referred from Endocrine Clinics at
The Aga Khan University Hospital and from the National
Institute of Child Health, Karachi. CAH diagnosis was
based on clinical presentation and hormonal investigation.
An independent clinical and biochemical evaluation of
the patients was also performed at the time of inclusion,
through a questionnaire. Informed consent for the study
was obtained from patient’s parents, or guardians.
Patients were characterized into salt wasters (SW), simple
virilizers (SV) and non-classical (NC) based on presenta-
tion and level of sodium, potassium and 17 hydroxy pro-
gesterone (17OHP).
CAH with SW was identified by the onset of failure to
thrive, vomiting, hyperkalaemia, hyponatraemia, azote-
mia, metabolic acidosis, dehydration and shock requiring
treatment with both mineralocorticoids and glucocorti-
coids. The SV form was identified by the presence of
ambiguous genitalia in newborn females and penile
enlargement, advanced bone age and pseudo precocious
puberty in affected male children.
Blood samples were collected in tubes containing
EDTA as anticoagulant. Genomic DNA was extracted
from leukocytes using Promega Wizard genomic DNA
purification kit (Promega, WI, USA). Purified DNA was
screened for mutations in CYP21A2 gene using Ampli-
fied Refractory Mutation Specific Polymerase Chain
Reaction (ARMS-PCR).
Mutation Analysis
ARMS-PCR was performed according to the protocol
described by Wedell et al. [7]. Briefly, CYP21A2 gene was
amplified in two overlapping fragments A and B, consist-
ing of 1147 bp and 2099 bp respectively. Amplification of
fragment A was carried in PCR buffer containing 0.5 μM
primer P1 and P48, 1.5mM MgCl2,0 . 2m Md N T P s ,
1u n i to fTaq DNA polymerase and 250 ng patient’s
DNA. Cycling was performed at 94°C for 30 sec, 56°C for
35 sec, and 72°C for 1.30 min for 35 cycles. Fragment B
was amplified using 0.5 μM of primers P4 and P55 and
250 ng DNA in 25 μl of High Fidelity PCR master mix
(Roche Diagnostics, USA). Cycling program for fragment
B was similar to fragment A, except for an increase in the
extension time to 2.30 min. In the second round PCR,
fragment A was amplified with primers specific for muta-
tions at nucleotide positions 659 (I2 splice) and 92 (Pro
31leu) and fragment B was assessed for mutations 1004
(Ile173Asn), 1388 (Val238Glu), 1688 (Val282Leu), 1768
(Leu308InsT), 1999 (Gln319stop) and 2113 (Arg357Trp).
Nucleotide positions refer to the CYP21A2 gene acces-
sion number M12792. Subsequent to PCR, amplified pro-
ducts were separated on 1% agarose gel and visualized by
ethidium bromide staining (figure 1).
Results
Table 1 summarizes clinical and biochemical details and
genotype status of CYP21A2 in our study participants.
At the time of diagnosis, mean age of the patients was
2.2 years. There were 14 phenotypic males and 15
females (female to male ratio of 1.07). Among females,
13 had features of prenatal virilization at birth and those
were initially considered to be male before the final
diagnosis. In 5 cases, male sex was preserved and they
were raised as male. One of the patients diagnosed for
CAH at the age of 47 years, turned out to be a case of
late diagnosis, although this patient had history of viri-
lizing symptoms since birth. According to the clinical
and laboratory investigations, 17 patients were salt
wasters, whereas 12 patients were simple virilizers. Med-
ian 17 OHP levels in salt wasters and in simple virilizers
were 140 ng/ml and 60 ng/ml respectively. 17 OHP
levels were consistently higher in salt wasters as com-
pared to simple virilizers but this difference was not sta-
tistically significant. However, hyponatremia and
hyperkalemia was significantly more marked in salt
wasters as compared to simple virilizers (p < 0.002).
The patients represented most of the major ethnic
groups of Pakistan (Urdu speaking 27%, Punjabi 21%,
Sindhi 17%, Pathans 14% and Afghanis 14%). Urdu speak-
ing and Afghanis comprised of the people who migrated
from India and Afghanistan at the time of sub-continent
partition and during the Afghanistan war. While Sindhi,
Punjabi and Pathans are the local inhabitants. Ethnicity
was not known in 6.8% of the cases. Parental consangui-
nity was present in 65% cases and was seen in all the eth-
nic groups examined. In 6 families more than 1 child was
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ID Sex Ethnicity Genotype Phenotype Na* K* 17 OHP
1 M - I2 splice/I2 splice SW 122 8.6 273.2
2 M - I2 splice/- SV 140 3.8 0.1
3 M Urdu Speaking Arg357Trp/- SV 137 4.4 57
4 F Urdu speaking I2 splice/I2 splice SW 124 6 >400
5 M Afghani ND SV 141 5.6 51
6 F Urdu speaking I2 splice/- SV 130 3.4 59.4
7 F Urdu speaking I2 splice/I2 splice SW 140 6.6 201
8 F Sindhi Pro31Leu/Ile173Asn/Arg357Trp/Gln319stop/Leu308insT/Val238Glu SW 125 7.9 400
9 F Punjabi Arg357Trp/Gln319stop/Leu3081nsT/ SW 136 5.2 1.4
10 F Sindhi Ile173Asn/Ile173Asn SV 139 4.3 226.4
11 M Punjabi Pro31Leu/Pro31Leu SW 98 7 185.8
12 M Pathan Ile173Asn/Arg357Trp/Gln319stop/Leu3081nsT SW 115 7.9 31.8
13 M Sindhi Arg357Trp/Gln319sto/Val238Glu SW 104 7.8 >400
14 F Punjabi Ile173Asn/Ile173Asn/Arg357Trp/Gln319stop/Leu308insT/Val238Glu SV - - 60.8
15 F Punjabi ND SV 143 3.6 150
16 M Pathan Arg357Trp/Gln319stop/Leu3081nsT SW 9.5
17 M Afghani Ile173Asn/Ile173Asn/Arg357Trp/Leu3081nsT SW 147 5.8 125
18 F Afghani Ile173Asn/Ile173Asn/Arg357Trp/Gln319stop/Leu308insT/Val238Glu SV 131 4.6 48.2
19 M Urdu speaking Ile173Asn/Ile173Asn/Arg357Trp/Gln319stop SV 141 4.6 >400
20 M Sindhi Pro31Leu/Arg357Trp/Val238Glu/Gln319stop SV 134 5.1 92
21 M Pathan I2 splice/- SV 139 5.2 9.2
22 F Punjabi ND SV 139 4.4 20
23 F Pathan I2 splice/I2 splice SW 128 5.3 166.4
24 M Urdu Speaking I2 splice/- SW 134 4.3 77.8
25 F Urdu speaking I2 splice/I2 splice SW 128 5.2 >20
26 M Afghani Pro31Leu/- SW 115 5.7 97.6
27 F Punjabi Ile173Asn/Ile173Asn SW 120 5 >400
28 F Urdu Speaking I2 splice/I2 splice SW - - 109.8
29 F Sindhi Ile173Asn/- SW 122 6 21.4
Na
+:: sodium; K
+: potassium; 17OHP: 17 hydroxyprogestron; SW: salt wasters; SV: simple virilizers
Figure 1 Illustrates CYP21A2 gene mutations detected by allele-specific PCR (Ia) fragment A (Ib) Pro31Leu (Ic) I2splice (IIa) fragment B
(IIb) Ileu173Asn (IIc) Gln319Stop, (IId) Arg357Trp (IIf) Val238Glu, (IIe) Leu308insT. jX174 and 50 bp DNA markers were used for fragment
size estimation.
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tions common to our patients’ population. Evaluation of
58 chromosomes revealed mutations in 45 (78%) chromo-
somes. The most frequently occurring mutation was I2
splice (27%) followed by Ile173Asn (26%), Arg 357 Trp
(19%), Gln319stop 16% and Leu308InsT (12%), whereas
Val282Leu was not detected in this study (figure 2).
Among Urdu speaking patients, (17%) were SW and (10%)
were SV, but overall 62% of them had I2 splice mutation.
High frequency (50%) of I2 mutation was also encountered
in Pathans. On the contrary, none of the patients from
Sind, Punjab and Afghanistan showed I2 mutation. When
compared among ethnic groups, Ile173Asn was most fre-
quently encountered in Sindhis (75%) and Afghanis (50%).
High level of compound heterozygosity was also noted in
Sindhis (60%), Pathans (50%) and Afghanis (50%). Out of
29 patients, 19 showed mutations in both the alleles,
whereas seven patients demonstrated mutation in one
allele. In addition, three patients were normal for all eight
mutations evaluated. Homozygosity was seen in 13
patients (44%). Out of these patients, 46% were homozy-
gous for both I2 splice and Ile173Asn mutations and 7.6%
were homozygous for Pro31Leu. Furthermore, heterozyg-
osity was noted in 10 (34%) patients. Relationship between
genotypes and the phenotypes were studied by comparing
disease manifestation in patients with different combina-
tion of mutations. I2 splice mutation was found to be asso-
ciated with SW in homozygous state, while presence of I2
splice mutation in one allele was found to be associated
with the SV form of the disease. Additionally, Ile173Asn
mutation was observed in both SW and SV forms and
Arg357Trp mutation was manifested in SW and SV in the
compound heterozygous state.
Discussion
The health issues of gender ambiguity are not well stu-
died in the Pakistan population. According to the local
literature, children with CAH are usually brought to
medical attention late in life [4,5]. It is also evident from
the present study that the median chronological age at
the time of diagnosis was comparatively high and only
41% cases were diagnosed during the newborn period
[4,8]. The age at diagnosis in our study is much higher,
in comparison to the countries that have an established
newborn screening program. However, the benefits of
screening for any disease in a country are dependent on
the existing healthcare system. The management of
genetic disorders has not received its due share in Paki-
stan, additionally; its healthcare system generally does
not address complex issues commonly seen in genetic
disorders including CAH patients [9,10]. Furthermore,
the matter is exacerbated by the high degree of parental
consanguinity seen in the local population (65.5%).
Therefore, there is a need to set up an infrastructure
with basic research and medical facilities with genetic
testing and counseling for CAH patients so that better
translational research concepts and intervention strate-
gies are designed to help consanguineous couples for
making informed and intelligent reproductive decisions.
Another important issue that relates to CAH in
Pakistan is the large ethnic diversity. Main ethnic
groups include Punjabis (44), Pathans (15%), Sindhis
(14%), Seraikis (11%), Muhajirs (8%), Balochis (4%) and
few others. In addition, Afghan refugees (registered in
Pakistan as Afghan Citizens) from neighboring Afgha-
nistan are also present [11]. Cultural norms of all eth-
nicities in Pakistan place a higher value on beneficence
and non-malfeasance relative to autonomy. They have
a long tradition of making family-centered health care
decisions. In this collective decision making process,
relatives receive information about patient’sd i a g n o s i s
and prognosis and make treatment choices, often with-
out the patient’s input especially if the patient is a
female. Illnesses like CAH are considered a family mat-
ter rather than an individual occurrence. Physicians are
challenged by tremendous diversity within a specific
ethnic group that influences the family and patient
response to medical issues of CAH and depends on
traditional views of gender roles, child bearing prac-
tices, views of marriage and relationships, common
religious and spiritual beliefs. Females born with
ambiguous genitalia continue to suffer from the conse-
quences of genital ambiguity, even if the diagnosis was
made at birth and in most of the cases they often do
not receive treatment. In our study, wrong gender
assignment to genotypic females is noted and in some
of them male sex was maintained due to late presenta-
tion and development of male gender identity at diag-
nosis (5 cases, 17.2%). It is a result of lack of
awareness, failure to diagnosis, false social beliefs, reli-
gious dogmas, pressure from relatives and society in
Figure 2 Distribution of common point mutations in CAH
patients (n = 29).
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mutations are sequences that are normally present in
the CYP21P gene, which can cause CYP21A2 gene
inactivation if transmitted to the functional gene by
the process of gene conversion. This accounts to
approximately 95% of all mutated CYP21A2 alleles.
The remaining 5% of the mutations are population
specific and are not derived from the pseudo gene.
Analysis of the CYP21A2 gene presents a challenge
because of the presence of this highly homologous
CYP21P. To overcome this obstacle, several selective
CYP21A2 gene amplification and mutation detection
procedures are developed [12-17]. In this study we
have adopted a strategy to detect eight most common
CYP21A2 point mutations based on hybridization with
allele specific primers that can discriminate between
mutation and wild type sequences, whereas pseudo
gene was excluded by selective amplification [7]. Our
results showed that seven CYP21A2 gene mutations
were detected in 78% (45/58) of CAH patients.
As shown in table 2, frequency of mutant alleles in
Pakistani patients was comparable to other parts of the
world including Iran and Turkey [18,19]. Among all
the known monogenic disorders, prenatal treatment
for CAH is the most effective. Therefore, there is a
need to establish a rapid, convenient prenatal screen-
ing method for diagnosis at least in families with
known CAH patients [6].
In this study, 29 patients of CAH due to 21 OH
deficiency were evaluated. Seventeen (59%) of them
exhibited the SW features and 12 were confirmed as
SV (41%). The frequencies for SW and SV forms of
the disease were different from published studies. For
example, in an Iranian study, SW constituted 70% of
the total CAH cases, whereas 30% were SV [18]. On
the other hand, the spectrum and frequency of muta-
tions including I2 splice, Ile173Asn and Gln319stop
presented in study were very similar to those reported
in the neighboring Indian population [20]. Our PCR
amplification failed in three cases. In two of them,
fragment B was not amplified, which could be due to
the presence of homozygous deletions/conversions
extending to exons 3, 4 and 5. Currently, it was not
possible for us to perform large deletions by methods
like MLPA, because of limited resources. However,
we like to include it in future studies. In one case
neither of the fragments amplified, which may be due
to homozygous gene deletion of CYP21A2 or to
transfer into CYP21A2 of pseudogene sequences that
include the 8 bp deletion in exon 3 [7]. Analysis of
homozygous individuals in our study showed that I2
mutation in the homozygous state was associated
with SW forms of the disease, whereas Ile173Asn was
associated with both SV and SW forms of the disease.
All these cases had markedly elevated 17OHP levels.
Compound heterozygosity was noted in both SV and
SW forms of the disease. In our study, compound
heterozygosity was seen moref r e q u e n t l yi nS i n d h i s ,
Pathans and Afghanis in comparison to Punjabis or
Urdu speaking communities. Moreover, compound
heterozygous genotypes were seen in SV, whereas a
higher frequency of homozygous genotypes was
observed in SW. The high rate of homozygosity in
SW may be due to high degree of parental consangui-
nity seen in our patients (70%). It is also possible that
the cases reported as homozygous in our study may
have been heterozygous, because we did not examine
the allele frequency for large deletions and conver-
sions [18]. It is our experience that the process of dis-
closure of all aspects of CAH and its clinical care will
require a collaborative effort. For optimal care,
experienced multidisciplinary teams in tertiary care
centers should openly communicate with patients and
their families. Thus allowing patients to participate in
making their own decisions, while respecting their
confidentiality and family’sc o n c e r n s .
Conclusion
It is evident from our study that CAH has clear pre-
sence in Pakistan, which is reflected in all major ethnic
groups. Extensive parental consanguinity and multi eth-
nic makeup are major factors leading to its widespread
prevalence. Therefore, there is a prompt necessity to set
up national and regional neonatal screening programs
while including CYP21A2 genotyping in the diagnostic
component to address this serious health issue.
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